Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00740792 · ClinicalTrials.gov registry record · Phase 3
A Study Evaluating the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies
A Phase 3 study of Seasonal Allergic Rhinitis, sponsored by Meda Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 776
- Enrollment target
- 20
- Study locations
NCT00740792 is a Phase 3 study of Seasonal Allergic Rhinitis that has completed, run by Meda Pharmaceuticals. The registered enrollment target is 776 participants, above the 620-participant average among 16 other Seasonal Allergic Rhinitis trials with a reported enrollment target (25% higher). The trial reports 20 study locations across 9 states.
The verdict
NCT00740792, a Phase 3 study of Seasonal Allergic Rhinitis, has completed, sponsored by Meda Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 776 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine if two allergy medications (formulated azelastine and fluticasone product) are more effective than placebo or either medication alone (azelastine or fluticasone)
Conditions Studied
Interventions
- DRUG placebo
- DRUG azelastine HCl/fluticasone propionate
- DRUG azelastine Hcl
- DRUG fluticasone propionate
Study Locations (20)
California
- Clinical Research Center - Encinitas
- AABI Associates Medical Group - Fountain Valley
- William Ebbling, MD Inc - Fresno
- Allergy & Asthma Care Center of So. Cal - Long Beach
- Allergy Research Foundation - Los Angeles
- Southern California Research - Mission Viejo
- Allergy Associates Medical Group Inc - San Diego
- Bensch Research Associates - Stockton
Georgia
- Clinical Research Atlanta - Atlanta
- Atlanta Allergy and Asthma Clinic - Stockbridge
- Clinical Research Atlanta - Stockbridge
Colorado
- Storms Clinical Research Institute - Colorado Springs
- Colorado Allergy and Asthma Centers - Denver
Minnesota
- Clinical Reseacrh Institute - Minneapolis
- Clinical Research Institute - Plymouth
Arizona
- Allergy, Asthma and Immunology Associates - Scottsdale
Illinois
- Sneeze, Wheeze and Itch Associates - Normal
Kansas
- Kansas City Allergy and Asthma - Overland Park
Massachusetts
- Northeast Medical Research Associates - North Dartmouth
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 776 participants |
| Start Date | 2008-08 |
| Est. Completion | 2008-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00740792
The ClinicalTrials.gov registry entry for NCT00740792 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 776 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 620-participant average among 16 other Seasonal Allergic Rhinitis trials with a reported enrollment target (25% higher). The listed sponsor is Meda Pharmaceuticals, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Seasonal Allergic Rhinitis appearing as the primary indexed condition, and to 4 interventions - of which placebo is the first listed.
NCT00740792 reports 20 study locations spanning 9 distinct geographic areas - top geographies include California, Georgia, Colorado.
Frequently Asked Questions
What is clinical trial NCT00740792 about?
NCT00740792 is a clinical study titled "A Study Evaluating the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies". The purpose of this study is to determine if two allergy medications (formulated azelastine and fluticasone product) are more effective than placebo or either medication alone (azelastine or fluticasone)
What is the current status of trial NCT00740792?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 776 participants. The study started on 2008-08. Estimated completion is 2008-11.
What conditions does trial NCT00740792 study?
This clinical trial studies the following conditions: Seasonal Allergic Rhinitis.
What interventions are being tested in trial NCT00740792?
The interventions under investigation include: placebo (DRUG), azelastine HCl/fluticasone propionate (DRUG), azelastine Hcl (DRUG), fluticasone propionate (DRUG).
Who is sponsoring clinical trial NCT00740792?
This trial is sponsored by Meda Pharmaceuticals, which has 19 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00740792 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Seasonal Allergic Rhinitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Efficacy and Safety of Fixed Dose Combination GSP 301 Nasal Spray (NS) in the Treatment of Seasonal Allergic Rhinitis (SAR)
COMPLETED · Phase 3
-
Safety and Efficacy of Ciclesonide in Pediatric Patients (6 to 11 Years of Age) With Seasonal Allergic Rhinitis (BY9010/M1-417)
COMPLETED · Phase 3
-
Study of an Investigational Nasal Aerosol or Placebo Nasal Aerosol in Children (Ages 6-11) With Seasonal Allergies
COMPLETED · Phase 3
-
Safety and Efficacy of Olopatadine HCl Nasal Spray in 6-11 Year Old Patients
COMPLETED · Phase 3
-
A Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjects 6-11 Years With Seasonal Allergic Rhinitis (SAR)
COMPLETED · Phase 3
-
Dose Selection Study of Efficacy and Safety of Different Doses of Grass MATA MPL and Grass MATA Using mEECs™
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.